GSK to abandon regulatory filings for arthritis drug as phase 3 trial fails

Oct. 27, 2022 4:48 AM ETGSK plc (GSK)PFE, SNY, REGN, MPSYF, MORBy: Ravikash, SA News Editor1 Comment

Senior Citizens Protest High Prescription Drug Prices

Don Murray

GSK (NYSE:GSK) on Thursday said that it will not proceed with regulatory submissions for otilimab to treat moderate to severe rheumatoid arthritis (RA) after the drug failed to meet the main goal of a trial.

The British pharma giant

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.